Webinar | FLT3 mutations in AML: Types, prevalence, and clinical significance скачать в хорошем качестве

Webinar | FLT3 mutations in AML: Types, prevalence, and clinical significance

The AML Hub held a webinar on November 19, 2025, titled, “Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice.” Here, we share one of the presentations, by Jorge Sierra, Hospital de la Santa Creu i Sant Pau, Barcelona, ES, discussing the types, prevalence, and clinical significance of FLT3 mutations in acute myeloid leukemia (AML). Sierra provided an overview of the role of FLT3-internal tandem duplication (ITD) and -tyrosine kinase domain (TKD) mutations in AML pathogenesis, and the differences in their molecular characteristics. He then discussed the prognostic value of FLT3-ITD and -TKD and concomitant mutations in patients with AML, and current risk stratification guidelines.